Cargando…

Trafficking protein TMED3 promotes esophageal squamous cell carcinoma

BACKGROUND: The molecular mechanisms of esophageal squamous cell carcinoma (ESCC) remain poorly understood. Transmembrane emp24 trafficking protein 3 (TMED3) acts as an oncogene or tumor suppressor gene in different cancers. Our study was to explore the clinicopathological significance and functiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuxian, Liu, Shiliang, Xie, Chunxia, Li, Qiaoqiao, Gao, Tiantian, Liu, Mengzhong, Xi, Mian, Zhao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chang Gung University 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267967/ https://www.ncbi.nlm.nih.gov/pubmed/35358714 http://dx.doi.org/10.1016/j.bj.2022.03.013

Ejemplares similares

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
por: Liu, Shiliang, et al.
Publicado: (2021)

TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR
por: Xie, An, et al.
Publicado: (2021)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy
por: Zhou, Sha, et al.
Publicado: (2023)

A novel immune-related prognostic signature based on Chemoradiotherapy sensitivity predicts long-term survival in patients with esophageal squamous cell carcinoma
por: Zhang, Zewei, et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
por: Zhou, Sha, et al.
Publicado: (2019)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
por: Cheng, Xingyuan, et al.
Publicado: (2023)

Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma
por: Jiang, Hui, et al.
Publicado: (2023)

M(1)A and m(7)G modification-related genes are potential biomarkers for survival prognosis and for deciphering the tumor immune microenvironment in esophageal squamous cell carcinoma
por: Wang, Ruixi, et al.
Publicado: (2023)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)

TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma
por: Gao, Wen, et al.
Publicado: (2022)

Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma
por: Wang, Yuting, et al.
Publicado: (2023)

Characteristics and Treatment of Brain Metastases from Esophageal Squamous Cell Carcinoma
por: Li, Qiaoqiao, et al.
Publicado: (2018)

TMED10 mediates the trafficking of insulin-like growth factor 2 along the secretory pathway for myoblast differentiation
por: Li, Tiantian, et al.
Publicado: (2023)

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
por: Li, Qiaoqiao, et al.
Publicado: (2012)

Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern
por: Bao, Yong, et al.
Publicado: (2013)

TMED2 promotes epithelial ovarian cancer growth
por: Shi-Peng, Gong, et al.
Publicado: (2017)

Depleting TMED3 alleviates the development of endometrial carcinoma
por: Zhang, Jin, et al.
Publicado: (2022)

The circular RNA CDR1as regulate cell proliferation via TMED2 and TMED10
por: Yang, Xue, et al.
Publicado: (2020)

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
por: Wu, Yingjia, et al.
Publicado: (2021)

TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling
por: Zheng, Hao, et al.
Publicado: (2016)

TMED family genes and their roles in human diseases
por: Zhou, Lv, et al.
Publicado: (2023)

TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma
por: Liu, ShiLiang, et al.
Publicado: (2017)

Unilateral Cervical Nodal Metastasis Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Patients Undergoing Chemoradiotherapy: A Retrospective Study
por: Zhang, Peng, et al.
Publicado: (2014)

The protein secretion modulator TMED9 drives CNIH4/TGFα/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases
por: Mishra, Sonakshi, et al.
Publicado: (2019)

Expression and Importance of TMED2 in Multiple Myeloma Cells
por: Ge, Xueling, et al.
Publicado: (2020)

Unconventional secretion: cargo channeling by TMED10
por: Nguyen, Tan A., et al.
Publicado: (2020)

Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer
por: Fang, Zheng, et al.
Publicado: (2022)

TMED3/RPS15A Axis promotes the development and progression of osteosarcoma
por: Xu, Wei, et al.
Publicado: (2021)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma
por: Pan, Chuqing, et al.
Publicado: (2021)

TMED2 as a marker of prognosis in breast cancer [Letter]
por: Schwarz, Megan Catherine, et al.
Publicado: (2019)

Expression of TMED3 is independently associated with colorectal cancer prognosis
por: Wang, Rong-Fei, et al.
Publicado: (2022)

TMED2 binding restricts SMO to the ER and Golgi compartments
por: Di Minin, Giulio, et al.
Publicado: (2022)

Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer
por: Lin, Xia, et al.
Publicado: (2019)

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma
por: Zhu, Yujia, et al.
Publicado: (2017)

Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Fu, Yizhen, et al.
Publicado: (2020)

Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2015)

Transmembrane p24 trafficking protein 10 (TMED10) inhibits mitochondrial damage and protects neurons in ischemic stroke via the c-Jun N-terminal kinase (JNK) signaling pathway
por: Li, Qiushi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_abesrij01off1rjhdmqdtrltn2